PubRank

Vincenzo Gentile

Author PubWeight™ 63.58‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2007 3.26
2 Treatment of varicocele in subfertile men: The Cochrane Review--a contrary opinion. Eur Urol 2006 2.18
3 Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003 2.17
4 Prostate cancer gene 3 and multiparametric magnetic resonance can reduce unnecessary biopsies: decision curve analysis to evaluate predictive models. Urology 2013 2.07
5 Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007 1.61
6 Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol 2013 1.60
7 Smoking as a risk factor for erectile dysfunction: data from the Andrology Prevention Weeks 2001-2002 a study of the Italian Society of Andrology (s.I.a.). Eur Urol 2005 1.52
8 Thulium laser supported nephron sparing surgery for renal cell carcinoma. J Urol 2013 1.28
9 Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003 1.27
10 Two-sided bulbar urethroplasty using dorsal plus ventral oral graft: urinary and sexual outcomes of a new technique. J Urol 2011 1.20
11 Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). Eur J Radiol 2011 1.09
12 Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010 1.04
13 Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 2006 0.95
14 Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer 2014 0.94
15 Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int 2012 0.94
16 Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer. Cancer Invest 2010 0.92
17 Long term patient satisfaction and quality of life with AMS700CX inflatable penile prosthesis. Arch Ital Urol Androl 2013 0.89
18 The emerging role of targeted therapy in renal cell carcinoma (RCC): is it time for a neoadjuvant or an adjuvant approach? Crit Rev Oncol Hematol 2011 0.88
19 Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. J Urol 2009 0.88
20 Supernumerary kidney laparoscopically treated. Can Urol Assoc J 2013 0.85
21 Management of urethral stent failure for recurrent anterior urethral strictures. Eur Urol 2009 0.85
22 Efficacy and safety of tadalafil in a Western European population of men with erectile dysfunction. BJU Int 2004 0.85
23 Superselective embolization of bladder arteries in the treatment of intractable bladder haemorrhage. Int J Urol 2005 0.85
24 Randomized trial comparing an anterograde versus a retrograde approach to open radical prostatectomy: results in terms of positive margin rate. Can Urol Assoc J 2010 0.85
25 Urethral pseudodiverticulum secondary to penile fracture and complete urethra dissection. Can Urol Assoc J 2013 0.84
26 In vivo 3D neuroanatomical evaluation of periprostatic nerve plexus with 3T-MR Diffusion Tensor Imaging. Eur J Radiol 2013 0.84
27 Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 2009 0.84
28 Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003 0.83
29 [Role of neuroendocrine cells in prostate cancer progression]. Urologia 2011 0.83
30 Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int 2009 0.83
31 Pain in the upper anterior-lateral part of the thigh in women affected by endometriosis: study of sensitive neuropathy. Fertil Steril 2013 0.82
32 Premature ejaculation results in female sexual distress: standardization and validation of a new diagnostic tool for sexual distress. J Urol 2012 0.82
33 Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer. Crit Rev Oncol Hematol 2012 0.82
34 Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review. Can Urol Assoc J 2012 0.81
35 Update on screening in prostate cancer based on recent clinical trials. Rev Recent Clin Trials 2011 0.81
36 Bladder cancer: a simple model becomes complex. Curr Genomics 2012 0.81
37 2D and 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy with erectile function correlation. Eur Radiol 2008 0.81
38 New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials 2008 0.80
39 Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR). Urol Oncol 2011 0.80
40 Predictors for response to intermittent androgen deprivation (IAD) in prostate cancer cases with biochemical progression after surgery. Urol Oncol 2011 0.80
41 Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. Urology 2008 0.80
42 Knotless "three-U-stitches" technique for urethrovesical anastomosis during laparoscopic radical prostatectomy. Int J Urol 2012 0.80
43 Use of multiparametric MR with neurovascular bundle evaluation to optimize the oncological and functional management of patients considered for nerve-sparing radical prostatectomy. J Sex Med 2012 0.80
44 Primary synovial sarcoma of the penis. J Urol 2002 0.79
45 Extracorporeal shock wave therapy in the treatment of Peyronie's disease: long-term results. Arch Ital Urol Androl 2010 0.79
46 Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia. Urol Int 2008 0.79
47 [Neuroendocrine target therapies for prostate cancer]. Urologia 2011 0.79
48 Incidental prostatic stromal tumor of uncertain malignant potential (STUMP): histopathological and immunohistochemical findings. Urologia 2012 0.79
49 Current and emerging strategies in bladder cancer. Anticancer Agents Med Chem 2012 0.78
50 Long-term experience with an anatomical anterograde approach to radical prostatectomy: results in terms of positive margin rate. Urol Int 2008 0.78
51 Reliability of PSA circulating cells as markers of metastatic prostate cancer. Scand J Clin Lab Invest 2004 0.78
52 Prospective open-label study on the efficacy and tolerability of a combination of nutritional supplements in primary infertile patients with idiopathic astenoteratozoospermia. Arch Ital Urol Androl 2012 0.77
53 Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer? BMC Cancer 2005 0.77
54 Chromogranin A expression in familial versus sporadic prostate cancer. Urology 2005 0.77
55 PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res 2011 0.77
56 Rome Consensus Conference - statement; human papilloma virus diseases in males. BMC Public Health 2013 0.77
57 Use of inflatable penile prostheses AMS CX with momentary squeeze in a patient with Peyronie's disease after removal of two previously implanted penile prostheses. Arch Ital Urol Androl 2014 0.76
58 A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine (Baltimore) 2016 0.75
59 Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report. Eur Urol 2007 0.75
60 Chronic bacterial prostatitis: efficacy of short-lasting antibiotic therapy with prulifloxacin (Unidrox®) in association with saw palmetto extract, lactobacillus sporogens and arbutin (Lactorepens®). BMC Urol 2014 0.75
61 Hyperhomocysteinemia as an Early Predictor of Erectile Dysfunction: International Index of Erectile Function (IIEF) and Penile Doppler Ultrasound Correlation With Plasma Levels of Homocysteine. Medicine (Baltimore) 2015 0.75
62 Reply: To PMID 24080222. Urology 2013 0.75
63 Value of magnetic resonance spectroscopy (MSR) and dynamic contrast-enhanced magnetic resonance (DCEMR) imaging for the characterization of high-grade prostatic intraepithelial neoplasia (HGPIN) foci. Urol Oncol 2009 0.75
64 Reply by authors. Arch Ital Urol Androl 2014 0.75
65 Penile subcutaneous fibrolipoma postaugmentative phalloplasty. Case Rep Urol 2013 0.75
66 [Clinical and diagnostic approach to erectile dysfunction]. Ann Ital Med Int 2004 0.75
67 Penile fracture: penoscrotal approach with degloving of penis after Magnetic Resonance Imaging (MRI). Arch Ital Urol Androl 2014 0.75
68 Use of 3D T2-weighted MR sequences for the assessment of neurovascular bundle changes after nerve-sparing radical retropubic prostatectomy (RRP): a potential diagnostic tool for optimal management of erectile dysfunction after RRP. J Sex Med 2009 0.75
69 Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy. Eur Urol 2007 0.75
70 Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 2004 0.75
71 Biopsy-derived Gleason artifact and prostate volume: experience using ten samples in larger prostates. Urol Int 2008 0.75
72 Penile prosthesis implant for erectile dysfunction: A new minimally invasive infrapubic surgical technique. Arch Ital Urol Androl 2016 0.75
73 Comparison between ultrasound-guided and digital-guided anesthesia before prostatic biopsy. Arch Ital Urol Androl 2012 0.75
74 Comparative effect of finasteride and dutasteride on chromogranin A levels. Anticancer Res 2010 0.75
75 Bilateral ex vivo repair and kidney autotransplantation for complex renal artery aneurysms: a case report and literature review. Int J Urol 2013 0.75
76 Bilateral varicocele: single transscrotal approach for Tauber antegrade sclerotherapy. Arch Ital Urol Androl 2003 0.75
77 [Preliminary resultson the use of autologous cell culture grafts of buccal mucosa in urethral repairs]. Urologia 2012 0.75
78 Oral ethinylestradiol in castration-resistant prostate cancer: a 10-year experience. Int J Urol 2014 0.75
79 [Current diagnostic procedure on neuroendocrine differentiation of prostate cancer]. Urologia 2011 0.75
80 Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia: clinical implications. Urol Int 2002 0.75
81 Evolution in varicocele sclerosing treatment: the ante/retrograde (A/R) approach. Arch Ital Urol Androl 2004 0.75
82 Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10. Urol Int 2003 0.75
83 Three-component hydraulic penile prosthesis malfunction due to penile fibrolipoma secondary to augmentative phalloplasty: A case report. Arch Ital Urol Androl 2016 0.75